Duopharma Biotech (Malaysia) Performance
| 7148 Stock | 1.22 0.03 2.40% |
The firm shows a Beta (market volatility) of -0.23, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Duopharma Biotech are expected to decrease at a much lower rate. During the bear market, Duopharma Biotech is likely to outperform the market. At this point, Duopharma Biotech Bhd has a negative expected return of -0.0447%. Please make sure to confirm Duopharma Biotech's treynor ratio, value at risk, and the relationship between the total risk alpha and maximum drawdown , to decide if Duopharma Biotech Bhd performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Duopharma Biotech Bhd has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Duopharma Biotech is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 158 M | |
| Total Cashflows From Investing Activities | -121.5 M | |
| Free Cash Flow | -71.8 M |
Duopharma |
Duopharma Biotech Relative Risk vs. Return Landscape
If you would invest 126.00 in Duopharma Biotech Bhd on November 28, 2024 and sell it today you would lose (4.00) from holding Duopharma Biotech Bhd or give up 3.17% of portfolio value over 90 days. Duopharma Biotech Bhd is generating negative expected returns and assumes 1.4212% volatility on return distribution over the 90 days horizon. Simply put, 12% of stocks are less volatile than Duopharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Duopharma Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Duopharma Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Duopharma Biotech Bhd, and traders can use it to determine the average amount a Duopharma Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0315
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 7148 |
Estimated Market Risk
| 1.42 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Duopharma Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Duopharma Biotech by adding Duopharma Biotech to a well-diversified portfolio.
Duopharma Biotech Fundamentals Growth
Duopharma Stock prices reflect investors' perceptions of the future prospects and financial health of Duopharma Biotech, and Duopharma Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Duopharma Stock performance.
| Return On Equity | 10.93 | |||
| Current Valuation | 1.78 B | |||
| Price To Book | 2.32 X | |||
| Price To Sales | 2.12 X | |||
| Revenue | 639.17 M | |||
| EBITDA | 121.38 M | |||
| Cash And Equivalents | 31.5 M | |||
| Total Debt | 297.8 M | |||
| Cash Flow From Operations | 43.2 M | |||
| Total Asset | 1.16 B | |||
About Duopharma Biotech Performance
By examining Duopharma Biotech's fundamental ratios, stakeholders can obtain critical insights into Duopharma Biotech's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Duopharma Biotech is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Things to note about Duopharma Biotech Bhd performance evaluation
Checking the ongoing alerts about Duopharma Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Duopharma Biotech Bhd help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Duopharma Biotech generated a negative expected return over the last 90 days | |
| Duopharma Biotech may become a speculative penny stock |
- Analyzing Duopharma Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Duopharma Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Duopharma Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Duopharma Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Duopharma Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Duopharma Biotech's stock. These opinions can provide insight into Duopharma Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Duopharma Stock
Duopharma Biotech financial ratios help investors to determine whether Duopharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Duopharma with respect to the benefits of owning Duopharma Biotech security.